| PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ... Journal of clinical oncology 30 (8), 777-782, 2012 | 519 | 2012 |
| Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer H Liang, LWT Cheung, J Li, Z Ju, S Yu, K Stemke-Hale, T Dogruluk, Y Lu, ... Genome research 22 (11), 2120-2129, 2012 | 307 | 2012 |
| AKT Inhibition in Solid Tumors With AKT1 Mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251-2259, 2017 | 290 | 2017 |
| Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203 AH Klopp, AR Yeung, S Deshmukh, KM Gil, L Wenzel, SN Westin, ... Journal of clinical oncology 36 (24), 2538-2544, 2018 | 287 | 2018 |
| PARP inhibitors in the management of ovarian cancer: ASCO guideline WP Tew, C Lacchetti, A Ellis, K Maxian, S Banerjee, M Bookman, ... Journal of Clinical Oncology 38 (30), 3468-3493, 2020 | 255 | 2020 |
| Endometrial cancer V Makker, H MacKay, I Ray-Coquard, DA Levine, SN Westin, D Aoki, ... Nature reviews Disease primers 7 (1), 88, 2021 | 235 | 2021 |
| Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome SN Westin, RA Lacour, DL Urbauer, R Luthra, DC Bodurka, KH Lu, ... Journal of Clinical Oncology 26 (36), 5965-5971, 2008 | 228 | 2008 |
| A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer PT Soliman, SN Westin, S Dioun, CC Sun, E Euscher, MF Munsell, ... Gynecologic oncology 146 (2), 234-239, 2017 | 223 | 2017 |
| Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ... The Lancet Oncology 20 (4), 570-580, 2019 | 222 | 2019 |
| Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ... Science translational medicine 9 (392), eaal5148, 2017 | 206 | 2017 |
| Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade … UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ... Annals of Oncology 28 (3), 512-518, 2017 | 191 | 2017 |
| Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy Y Fang, DJ McGrail, C Sun, M Labrie, X Chen, D Zhang, Z Ju, CP Vellano, ... Cancer cell 35 (6), 851-867. e7, 2019 | 184 | 2019 |
| Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device N Pal, RR Broaddus, DL Urbauer, N Balakrishnan, A Milbourne, ... Obstetrics & Gynecology 131 (1), 109-116, 2018 | 183 | 2018 |
| A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) BJ Monk, C Parkinson, MC Lim, DM O'malley, A Oaknin, MK Wilson, ... Journal of Clinical Oncology 40 (34), 3952-3964, 2022 | 181 | 2022 |
| Clinical cancer advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology J Heymach, L Krilov, A Alberg, N Baxter, SM Chang, RB Corcoran, ... Journal of Clinical Oncology 36 (10), 1020-1044, 2018 | 174 | 2018 |
| Clinical cancer advances 2020: annual report on progress against cancer from the American Society of Clinical Oncology MJ Markham, K Wachter, N Agarwal, MM Bertagnolli, SM Chang, W Dale, ... Journal of Clinical Oncology 38 (10), 1081, 2020 | 150 | 2020 |
| Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology PT Soliman, M Frumovitz, CC Sun, R Dos Reis, KM Schmeler, AM Nick, ... Gynecologic oncology 123 (2), 333-336, 2011 | 143 | 2011 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 122 | 2018 |
| Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer GM Rauch, H Kaur, H Choi, RD Ernst, AH Klopp, P Boonsirikamchai, ... Radiographics 34 (4), 1082-1098, 2014 | 118 | 2014 |
| Overall survival after pelvic exenteration for gynecologic malignancy SN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ... Gynecologic oncology 134 (3), 546-551, 2014 | 114 | 2014 |
